AU2016288237B2 - Compositions and methods for delivery of gene editing tools using polymeric vesicles - Google Patents

Compositions and methods for delivery of gene editing tools using polymeric vesicles Download PDF

Info

Publication number
AU2016288237B2
AU2016288237B2 AU2016288237A AU2016288237A AU2016288237B2 AU 2016288237 B2 AU2016288237 B2 AU 2016288237B2 AU 2016288237 A AU2016288237 A AU 2016288237A AU 2016288237 A AU2016288237 A AU 2016288237A AU 2016288237 B2 AU2016288237 B2 AU 2016288237B2
Authority
AU
Australia
Prior art keywords
poly
dna
composition
gene editing
polymersome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016288237A
Other languages
English (en)
Other versions
AU2016288237A1 (en
Inventor
P. Peter Ghoroghchian
Jivan Namdeo YEWLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poseida Therapeutics Inc
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of AU2016288237A1 publication Critical patent/AU2016288237A1/en
Application granted granted Critical
Publication of AU2016288237B2 publication Critical patent/AU2016288237B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016288237A 2015-07-02 2016-07-01 Compositions and methods for delivery of gene editing tools using polymeric vesicles Ceased AU2016288237B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562187942P 2015-07-02 2015-07-02
US62/187,942 2015-07-02
US201662322346P 2016-04-14 2016-04-14
US62/322,346 2016-04-14
US15/199,021 US20170000743A1 (en) 2015-07-02 2016-06-30 Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
US15/199,021 2016-06-30
PCT/US2016/040673 WO2017004509A1 (en) 2015-07-02 2016-07-01 Compositions and methods for delivery of gene editing tools using polymeric vesicles

Publications (2)

Publication Number Publication Date
AU2016288237A1 AU2016288237A1 (en) 2018-01-25
AU2016288237B2 true AU2016288237B2 (en) 2022-04-14

Family

ID=57609243

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016288237A Ceased AU2016288237B2 (en) 2015-07-02 2016-07-01 Compositions and methods for delivery of gene editing tools using polymeric vesicles

Country Status (8)

Country Link
US (1) US20170000743A1 (https=)
EP (1) EP3317414A4 (https=)
JP (2) JP6993966B2 (https=)
CN (1) CN108699563A (https=)
AU (1) AU2016288237B2 (https=)
CA (1) CA2991109A1 (https=)
HK (1) HK1255209A1 (https=)
WO (1) WO2017004509A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
US11213594B2 (en) 2016-04-29 2022-01-04 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
ES3051391T3 (en) 2016-10-06 2025-12-29 Poseida Therapeutics Inc Inducible caspases and methods for use
JP2020523383A (ja) 2017-06-14 2020-08-06 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性ｔ細胞受容体の標的置換
CA3124103A1 (en) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
US20220372105A1 (en) 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
AU2020407235A1 (en) 2019-12-20 2022-07-07 Poseida Therapeutics, Inc. Anti-MUC1 compositions and methods of use
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
GB202004254D0 (en) 2020-03-24 2020-05-06 Puridify Ltd Characterization of gene therapy vectors
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
CN117355607A (zh) * 2021-04-13 2024-01-05 阿森纳生物科学公司 非病毒同源性介导的末端连接
EP4413141A1 (en) 2021-10-04 2024-08-14 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
EP4482967A1 (en) 2022-02-23 2025-01-01 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023193665A1 (zh) * 2022-04-07 2023-10-12 威海纽兰生物科技有限公司 基于细胞外囊泡酯酶响应药物递送载体及其制备方法和用途
EP4646189A1 (en) * 2023-01-06 2025-11-12 Vianautis Bio Limited Polymersomes for delivery of nucleic acid cargoes
EP4669746A1 (en) 2023-02-21 2025-12-31 Poseida Therapeutics, Inc. COMPOSITIONS AND GENOMIC EDITING PROCESSES
KR20250166122A (ko) 2023-02-21 2025-11-27 포세이다 테라퓨틱스, 인크. 게놈 편집을 위한 조성물 및 방법
CN121335979A (zh) 2023-05-17 2026-01-13 波西达治疗公司 靶向hbg1和hbg2的组合物及其使用方法
WO2025096980A1 (en) 2023-11-02 2025-05-08 Poseida Therapeutics, Inc. Compositions targeting klkb1 and methods of use thereof
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130202712A1 (en) * 2010-03-02 2013-08-08 Vindico Nanobio Technology, Inc. Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease
US20140363496A1 (en) * 2011-01-07 2014-12-11 Vindico NanoBio Technology Inc. Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
WO2015191693A2 (en) * 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089579A2 (en) * 2000-05-19 2001-11-29 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
US20040265835A1 (en) * 2003-06-30 2004-12-30 Lemaster David M. Method of sorting vesicle-entrapped, coupled nucleic acid-protein displays
CA2756670A1 (en) * 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
TWI576432B (zh) * 2009-04-07 2017-04-01 陶氏農業科學公司 序列特異性核酸酶之奈米粒子媒介式遞送技術
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
AU2012249390B2 (en) * 2011-04-27 2017-03-30 Amyris, Inc. Methods for genomic modification
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
RU2662932C2 (ru) * 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
WO2014194190A1 (en) * 2013-05-30 2014-12-04 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130202712A1 (en) * 2010-03-02 2013-08-08 Vindico Nanobio Technology, Inc. Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease
US20140363496A1 (en) * 2011-01-07 2014-12-11 Vindico NanoBio Technology Inc. Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
WO2015191693A2 (en) * 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing

Also Published As

Publication number Publication date
EP3317414A4 (en) 2019-03-13
EP3317414A1 (en) 2018-05-09
CN108699563A (zh) 2018-10-23
CA2991109A1 (en) 2017-01-05
AU2016288237A1 (en) 2018-01-25
WO2017004509A1 (en) 2017-01-05
JP2019165745A (ja) 2019-10-03
US20170000743A1 (en) 2017-01-05
JP2018532408A (ja) 2018-11-08
HK1255209A1 (zh) 2019-08-09
JP6993966B2 (ja) 2022-02-04

Similar Documents

Publication Publication Date Title
AU2016288237B2 (en) Compositions and methods for delivery of gene editing tools using polymeric vesicles
EP3449004B1 (en) Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
Kazemian et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components
Sahel et al. CRISPR/Cas9 genome editing for tissue‐specific in vivo targeting: nanomaterials and translational perspective
Ashok et al. Lipid-and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9
Givens et al. Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics
Allemailem et al. Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management
Li et al. Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice
Kauffman et al. Materials for non-viral intracellular delivery of messenger RNA therapeutics
WO2019126589A1 (en) Micelles for complexation and delivery of proteins and nucleic acids
JP2018532408A5 (https=)
CN106029880A (zh) 核苷酸重复障碍中CRISPR-Cas系统的组合物和使用方法
Ma et al. Bioinspired spatiotemporal management toward RNA therapies
Wang et al. Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems
Yang et al. Multivalent peptide-functionalized bioreducible polymers for cellular delivery of various RNAs
Geinguenaud et al. Vectorization of nucleic acids for therapeutic approach: tutorial review
CN120787165A (zh) 用于递送核酸载物的纳米颗粒
Tuyen Ho et al. Bioinspired and biomimetic gene delivery systems
Eksi et al. Nanodelivery in gene therapy: unlocking the potential for precision medicine
Kanduri et al. Current advances toward the encapsulation of Cas9
Singh et al. Advancements in RNA-based therapies from bench to bedside
Swami et al. Diseases originate and terminate by genes: unraveling nonviral gene delivery
Kola et al. RNA-based vaccines and therapeutics against intracellular pathogens
Iqbal et al. Polymer-Mediated Delivery of CRISPR-Cas9 Genome-Editing Therapeutics for CNS Disease
Sousa et al. In Vitro CRISPR/Cas9 transfection and gene-editing mediated by multivalent cationic liposome–DNA complexes. Pharmaceutics. 2022; 14: 1087

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired